3,5,7,3',4'-Pentahydroxyflavonol

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 3,5,7,3',4'-Pentahydroxyflavonol
• 英文别名: 2-(3,4-dihydroxyphenyl)-3,3,5,7-tetrahydroxy-2H-chromen-4-one
• 化学式: C₁₅H₁₂O₈
• 分子量: 320.25
• InChiKey: NCICANWTHWJLJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  148
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• Use of myricetin or derivatives thereof as a cathepsin k inhibitor
  申请人：Jilinsheng Jinziyuan Biotechnology Ltd.

  公开号：EP2762137A1

  公开（公告）日：2014-08-06

  This invention is directed to a novel inhibitor on collagen degradation caused by the activity of a human cathepsin K rising. In particular, the inhibitor is myricetin or derivatives thereof. The invention also relates to use of the novel inhibitor to manufacture a medicament in a form of pharmaceuticals, foods, nutraceuticals or cosmetics for the prevention, amelioration and/or treatment of pathological symptoms or diseases associated with collagen degradation. Alternatively, the present invention is further directed to addition of the novel inhibitor to a medicament, food, nutraceutical or cosmetics used for the treatment, amelioration and/or prevention of the disease or pathological symptoms associated with collagen degradation by the increased human cathepsin K activety. The invention also provide the methods for treating, ameliorating and/or preventing the symptoms or diseases, comprising administering an effective amount of the medicament to a subject in need thereof.

  本发明涉及一种新型抑制剂，可抑制人类酪蛋白酶 K 活性引起的胶原降解。特别是，该抑制剂是杨梅素或其衍生物。本发明还涉及使用这种新型抑制剂制造药品、食品、营养保健品或化妆品，以预防、改善和/或治疗与胶原蛋白降解有关的病理症状或疾病。或者，本发明还进一步涉及将新型抑制剂添加到用于治疗、改善和/或预防与胶原蛋白降解有关的疾病或病理症状的药物、食品、营养品或化妆品中。本发明还提供了治疗、改善和/或预防症状或疾病的方法，包括向有需要的受试者施用有效量的药物。
• USE OF MYRICETIN OR DERIVATIVES THEREOF AS A CATHEPSIN K INHIBITOR
  申请人：JILINSHENG JINZIYUAN BIOTECHNOLOGY LTD

  公开号：US20140221472A1

  公开（公告）日：2014-08-07

  This invention is directed to a novel inhibitor on collagen degradation caused by the activity of a human cathepsin K rising. In particular, the inhibitor is myricetin or derivatives thereof. The invention also relates to use of the novel inhibitor to manufacture a medicament in a form of pharmaceuticals, foods, nutraceuticals or cosmetics for the prevention, amelioration and/or treatment of pathological symptoms or diseases associated with collagen degradation. Alternatively, the present invention is further directed to addition of the novel inhibitor to a medicament, food, nutraceutical or cosmetics used for the treatment, amelioration and/or prevention of the disease or pathological symptoms associated with collagen degradation by the increased human cathepsin K actively. The invention also provide the methods for treating, ameliorating and/or preventing the symptoms or diseases, comprising administering an effective amount of the medicament to a subject in need thereof.
• [EN] DIHYDROMYRICETIN FOR THE TREATMENT OF DISEASES AND DISORDERS OF THE GLUTAMATERGIC SYSTEM<br/>[FR] DIHYDROMYRICÉTINE POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES DU SYSTÈME GLUTAMATERGIQUE
  申请人：UNIV CALIFORNIA

  公开号：WO2014007853A1

  公开（公告）日：2014-01-09

  Disclosed herein are methods and compositions for treating a disease or disorder of the glutamatergic system, e.g., Alzheimer's disease, neuron damage and/or loss, and seizures, or a symptom thereof, e.g., decreased cognitive function, in a subject which comprises administering dihydromyricetin (DHM), an analog of DHM, or a metabolite of DHM to the subject.